Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Tuberculosis kills more people than any other pathogen and the need for a universally effective vaccine has never been greater. An effective vaccine will be a key tool in achieving the targets set by WHO in the End TB Strategy. Tuberculosis vaccine development is difficult and slow. Substantial progress has been made in research and development of tuberculosis vaccines in the past 20 years, and two clinical trial results from 2018 provide reason for optimism. However, many challenges to the successful licensure and deployment of an effective tuberculosis vaccine remain. The development of new tools for vaccine evaluation might facilitate these processes, and continued collaborative working and sustained funding will be essential.

Original publication

DOI

10.1016/s2213-2600(19)30274-7

Type

Journal article

Journal

The Lancet. Respiratory medicine

Publication Date

09/2019

Volume

7

Pages

810 - 819

Addresses

The Jenner Institute, University of Oxford, Oxford, UK. Electronic address: helen.mcshane@ndm.ox.ac.uk.

Keywords

Humans, Tuberculosis, Tuberculosis Vaccines, Research